Leaps by Bayer backs a protein engineering startup taking on Aimmune — and Nestlé — in peanut allergy

Little capsules of peanut powder drove Nestlé’s $2.6 billion buyout of Aimmune. Now, with $40 million in new funding, a fledgling biotech is promising to bring a more sophisticated version of that protein therapy that can go much, much further.